For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and Attruby represents a true change. These innovative therapies protect the transthyretin protein, slowing its destructive build-up and alleviating the impact of the illness. Individuals are now reporting improvements in… Read More